With an initial focus on oncology, our programs leverage the advanced capabilities of our technology to develop therapies against challenging targets as supported by solid clinically relevant in vivo data.
THE NEXT FRONTIER IN GENE EDITING
Our lead internal program in B-cell lymphoma unlocks a new frontier in CAR-T developments using our platform’s high frequencies of homology-directed repair to deliver in-vivo CAR insertions; while our program in non small cell lung cancer targets KRAS, a highly prized undruggable oncology target, and represents the first systemically administered ribonucleoprotein CRISPR system achieving targeted delivery to a solid tumor. In both programs, the complete eradication of the targeted tumors was observed at low doses.
Partner with us
Our company is strategically oriented towards the development of partnered programs. By compounding the advanced capabilities of our platform with the target or indication of your choice we could shape the next generation of gene editing therapeutics. Contact us to learn more.